Selective HDAC Inhibitors for HIV Latency Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors used in treating HIV infection are not selective and cause adverse effects, making them unsuitable for individuals on combination antiretroviral therapy (cART).
Innovation Solution
Development of novel, subtype-selective histone deacetylase (HDAC) inhibitors, represented by Compounds of Formula I, to activate HIV latency and potentially cure HIV infection alone or in combination with cART.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reverse transcriptase inhibitors are used to treat HIV infection, then viral replication is inhibited, but the virus develops resistance through mutation
Solution Approach 1:
The patent introduces histone deacetylase inhibitors as intermediary compounds that modify the cellular environment to enhance antiviral efficacy. These compounds act as mediators between the host cell and the virus, creating an unfavorable environment for viral replication without directly targeting the viral reverse transcriptase, thereby reducing selective pressure for resistance mutations.
Solution Approach 2:
The patent changes the therapeutic parameter from direct viral enzyme inhibition to host cell epigenetic modulation. By altering histone acetylation status, the treatment changes the chromatin structure and gene expression patterns in infected cells, creating a cellular environment that is less permissive to viral replication and reducing the emergence of resistant viral strains.
2Reliability
If multiple antiretroviral drugs are combined to prevent resistance, then treatment effectiveness is maintained, but side effects and toxicity increase
Solution Approach 1:
The histone deacetylase inhibitor serves multiple functions simultaneously: it enhances the efficacy of reverse transcriptase inhibitors, prevents viral resistance development, and modulates the host cellular environment to be less favorable for viral replication. This multi-functionality allows for reduced doses of conventional antiretroviral drugs, thereby reducing toxicity while maintaining resistance prevention.
Solution Approach 2:
The HDAC inhibitor acts as a cellular mediator that amplifies the effect of conventional antiretroviral drugs, allowing for lower doses of these drugs to achieve the same therapeutic effect. This intermediary作用 reduces the direct toxic burden on the patient while maintaining the preventive effect against resistance.
3Reliability
If reverse transcriptase inhibitors are administered at high doses to prevent resistance, then viral replication is suppressed, but adverse reactions increase
Solution Approach 1:
The patent changes the dosing parameter by using lower doses of reverse transcriptase inhibitors in combination with HDAC inhibitors. The HDAC inhibitor enhances the antiviral effect, allowing reduction of the RTI dose while maintaining suppression of viral replication, thereby reducing adverse reactions associated with high-dose RTI monotherapy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Compounds of Formula I effectively activate HIV production in latent infected cells, offering a potential cure for HIV infection with reduced adverse effects.
Implementation Method 1
inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
Data Source
AI summary
The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, Ra, Rb, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.